Mediation analysis of the molecular phenotypes in a severe MASH-like liver injury mouse model.

Authors

Zhuolin Song, Volodymyr P Tryndyak, Rose A Willett, Igor P Pogribny, Ivan Rusyn, Fred A Wright

Published in

Toxicological sciences : an official journal of the Society of Toxicology. Volume 208. Issue 1. Pages 155-166. Nov 01, 2025.

Abstract

Metabolic dysfunction-associated steatohepatitis (MASH), a severe form of fatty liver disease, is a leading cause of cirrhosis and lacks effective therapies. Understanding the molecular mediators of disease progression remains a critical gap. This study aimed to investigate the roles of molecular phenotypes as mediators of MASH disease features in a diet-induced mouse model. Data used for these analyses were from a previous study where male and female CC042 mice were fed either a control or high-fat, high-sucrose (HF/HS) diet for 20, 40, or 60 weeks. Associations and mediated relationships between molecular and metabolic phenotypes and histopathologic markers of liver injury, inflammation, and lipid accumulation were assessed using regression modeling and causal mediation analyses. We observed strong associations between the HF/HS diet and duration of treatment and liver pathology, with a limited effect of sex. Mediation analysis revealed that liver lipid phenotypes, particularly monounsaturated and polyunsaturated fatty acids, consistently mediated the effects of diet on liver disease scores. Tumor necrosis factor alpha and C-X-C motif chemokine ligand 10, despite being treatment-induced, showed modest evidence of mediation on MASH or specific liver disease outcomes. Serum insulin showed modest mediation of inflammation and osmium staining, while serum glucose and triglycerides were not significant mediators. These findings highlight evidence that liver lipid metabolism may act as a primary mediator of MASH progression in this mouse model. The study underscores the value of mediation analysis for improved characterization of metabolic pathways in disease pathogenesis and supports the use of serum lipids as accessible biomarkers for clinical risk stratification and therapeutic targeting in MASH.

PMID:
40795813
Bibliographic data and abstract were imported from PubMed on 09 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.